Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
Quick Facts
What This Study Found
Heteroclitic CALRMUT peptides elicited a CD8+ T cell response in patients, unlike native peptides.
Key Numbers
How They Did This
The study analyzed MHC-I allele frequencies in patients and tested immune responses to modified peptides in human samples and mouse models.
Why This Research Matters
This research highlights a potential new approach to cancer vaccination that could improve outcomes for patients with specific genetic mutations.
What This Study Doesn't Tell Us
The study primarily focused on specific patient cohorts, which may limit the generalizability of the findings.
Trust & Context
- Original Title:
- Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
- Published In:
- Science translational medicine, 14(649), eaba4380 (2022)
- Authors:
- Gigoux, Mathieu, Holmström, Morten O, Zappasodi, Roberta, Park, Joseph J, Pourpe, Stephane, Bozkus, Cansu Cimen, Mangarin, Levi M B, Redmond, David, Verma, Svena, Schad, Sara, George, Mariam M, Venkatesh, Divya, Ghosh, Arnab, Hoyos, David, Molvi, Zaki, Kamaz, Baransel, Marneth, Anna E, Duke, William, Leventhal, Matthew J, Jan, Max, Ho, Vincent T, Hobbs, Gabriela S, Knudsen, Trine Alma, Skov, Vibe, Kjær, Lasse, Larsen, Thomas Stauffer, Hansen, Dennis Lund, Lindsley, R Coleman, Hasselbalch, Hans, Grauslund, Jacob H, Lisle, Thomas L, Met, Özcan, Wilkinson, Patrick, Greenbaum, Benjamin, Sepulveda, Manuel A, Chan, Timothy, Rampal, Raajit, Andersen, Mads H, Abdel-Wahab, Omar, Bhardwaj, Nina, Wolchok, Jedd D, Mullally, Ann, Merghoub, Taha
- Database ID:
- RPEP-06138
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06138APA
Gigoux, Mathieu; Holmström, Morten O; Zappasodi, Roberta; Park, Joseph J; Pourpe, Stephane; Bozkus, Cansu Cimen; Mangarin, Levi M B; Redmond, David; Verma, Svena; Schad, Sara; George, Mariam M; Venkatesh, Divya; Ghosh, Arnab; Hoyos, David; Molvi, Zaki; Kamaz, Baransel; Marneth, Anna E; Duke, William; Leventhal, Matthew J; Jan, Max; Ho, Vincent T; Hobbs, Gabriela S; Knudsen, Trine Alma; Skov, Vibe; Kjær, Lasse; Larsen, Thomas Stauffer; Hansen, Dennis Lund; Lindsley, R Coleman; Hasselbalch, Hans; Grauslund, Jacob H; Lisle, Thomas L; Met, Özcan; Wilkinson, Patrick; Greenbaum, Benjamin; Sepulveda, Manuel A; Chan, Timothy; Rampal, Raajit; Andersen, Mads H; Abdel-Wahab, Omar; Bhardwaj, Nina; Wolchok, Jedd D; Mullally, Ann; Merghoub, Taha. (2022). Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.. Science translational medicine, 14(649), eaba4380. https://doi.org/10.1126/scitranslmed.aba4380
MLA
Gigoux, Mathieu, et al. "Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.." Science translational medicine, 2022. https://doi.org/10.1126/scitranslmed.aba4380
RethinkPeptides
RethinkPeptides Research Database. "Calreticulin mutant myeloproliferative neoplasms induce MHC-..." RPEP-06138. Retrieved from https://rethinkpeptides.com/research/gigoux-2022-calreticulin-mutant-myeloproliferative-neoplasms
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.